Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AddLife ABCHIX:ALIFBS 86 3-Year RORE % is 66.44 as of Jun. 2026. GuruFocus rates CHIX:ALIFBS with a GF Score™ of 86/100 and a GF Value™ of kr147.90 (Fairly Valued). The stock has 5 warning signs investors should review. Among 775 Medical Devices & Instruments companies, AddLife AB ranks better than 88.26% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
AddLife AB's 3-Year RORE % for the quarter that ended in Jun. 2026 was 66.44%.
The industry rank for AddLife AB's 3-Year RORE % or its related term are showing as below:
CHIX:ALIFBs's 3-Year RORE % is ranked better than 88.26% of 775
companies
in the Medical Devices & Instruments industry
Industry Median: -4.03
vs CHIX:ALIFBs: 66.44
AddLife AB (CHIX:ALIFBs) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
AddLife AB 3-Year RORE % Related Terms
AddLife AB 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for AddLife AB's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALIFBS vs ISRG, BDX, MDLN: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, AddLife AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AddLife AB 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where AddLife AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
AddLife AB (CHIX:ALIFBS) has a 3-Year RORE % of 66.44 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on AddLife AB and its competitors. According to the industry distribution chart, AddLife AB ranks #91 out of 775 companies in the Medical Devices & Instruments industry, placing it in the top 11.7%.
Is AddLife AB's 3-Year RORE % too high?
AddLife AB's current 3-Year RORE % is 66.44. Based on the distribution chart, AddLife AB ranks #91 out of 775 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AddLife AB has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's 3-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AddLife AB ranks #91 out of 775 companies for 3-Year RORE %. This places AddLife AB in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on AddLife AB and its competitors. AddLife AB's current 3-Year RORE % is 66.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
Based on GuruFocus' analysis, AddLife AB (CHIX:ALIFBS) is currently considered Fairly Valued. The stock's GF Value™ is kr147.90, compared to a current price of kr159.05 — trading 7.5% above its estimated fair value. The current 3-Year RORE % is 66.44. AddLife AB's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For AddLife AB (CHIX:ALIFBS), the current 3-Year RORE % is 66.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (CHIX:ALIFBS) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of kr159.05 is trading 7.5% above its estimated GF Value™ of kr147.90.
GuruFocus considers AddLife AB to be Fairly Valued.
Key valuation signals for CHIX:ALIFBS:
3-Year RORE %: 66.44
GF Value™: kr147.90 vs. price of kr159.05 (7.5% above fair value)
No single metric tells the full story. See the CHIX:ALIFBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
86GF Score
Get the complete analysis for CHIX:ALIFBS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALIFBS has been successfully added to your 
